Funkce: odborný pracovník v laboratorních metodách
Sekce: nádorové genomiky
Telefon: 532 234 207
E-mail:
Vzdělání
1992 titul Mgr., obor molekulární biologie a genetika; Přírodovědecká fakulta, Masarykova Univerzita, Brno
1996 titul Dr., obor genetika; Přírodovědecká fakulta, Masarykova Univerzita, Brno
2001 atestace v oboru Vyšetřovací metody v lékařské genetice
Dosavadní zaměstnání
1993-1995: University of Michigan Medical Center, Ann-Arbor, USA, Laboratoř prof. Davida M. Kurnita. Research assistant
1996-1999: Masarykův onkologický ústav, Brno; Oddělení buněčné a molekulární onkologie
1999-2002: Výzkumný ústav zdraví dítěte, Brno; Oddělení biochemické a molekulární genetiky
2002-dosud: Fakultní nemocnice Brno; Centrum molekulární biologie a genové terapie, Interní hematoonkologická klinika
Členství v odborných společnostech
Česká hematologická společnost
European Research Initiative on CLL (ERIC)
Oblast zájmu
chronická lymfocytární leukémie
TP53
syntetická letalita
Publikace k tématu (posledních 5 let)
Trbusek M, Smardova J, Malcikova J, et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011;29:2703-8.
Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, et al. European Research Initiative on CLL (ERIC). ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012;26:1458-61.
Doubek M, Trbusek M, Malcikova J, et al. Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:1817-9.
Navrkalova V, Sebejova L, Zemanova J, Kminkova J, Kubesova B, Malcikova J, Mraz M, Smardova J, Pavlova S, Doubek M, Brychtova Y, Potesil D, Nemethova V, Mayer J, Pospisilova S, Trbusek M. ATMmutations uniformly lead to ATM dysfunctionin chronic lymphocytic leukemia: Application of functional test using doxorubicin. Haematologica2013;98:1124-31.
Navrkalova V, Sebejova L, Zemanova J, Jaskova Z, Trbusek M. The p53 pathway induction is not primarily dependent on ATM activity upon fludarabine treatment in chronic lymphocytic leukemia cells. Leuk Lymphoma 2013;54:1840-3.
Trbusek M, Malcikova J. TP53 aberrations in chronic lymphocytic leukemia. Adv Exp Med Biol 2013;792:109-31. (published also as a chapter in book Advances in Chronic Lymphocytic Leukemia, Springer, New York).
Sebejova L, Borsky M, Jaskova Z, Potesil D, Navrkalova V, Malcikova J, Sramek M, Doubek M, Loja T, Pospisilova S, Mayer J, Trbusek M. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab. Exp Hematol 2014;42:867-74.
te Raa GD, Malcikova J, Mraz M, Trbusek M, et al. Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays: an ERIC-wide approach. Br J Haematol 2014;167:565-9.
Malcikova J, Stalika E, Davis Z, Plevova K, Trbusek M, et al. The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors. Br J Haematol 2014;166:621-5.
Te Raa D, GD, Derks IA, Navrkalova V, Skowronska A, Moerland PD, van Laar J, Oldreive C, Monsuur H, Trbusek M et al. The impact of SF3B1 mutations in CLL on DNA-damage response. Leukemia 2015;29:1133-42.
Malcikova J, Stano-Kozubik K, Tichy B, Kantorova B, Pavlova S, Tom N, Radova L, Smardova J, Pardy F, Doubek M, Brychtova Y, Mraz M, Plevova K, Diviskova E, Oltova A, Mayer J, Pospisiova S, Trbusek M. Detailed analysis of therapy-driven clonal evolution of TP53 mutations. Leukemia 2015;29:877-85.
Doubek M, Brychtova Y, Panovska A, Sebejova L, Stehlikova O, Chovancova J, Malcikova J, Smardova J, Plevova K, Volfova P, Trbusek M et al. Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study. Am J Hematol 2015;90:417-21.
Sutton LA, Ljungstrom V, Mansouri L, Young , Cortese D, Navrkalova V, Malcikova J, Muggen AF, Trbusek M et al. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting. Haematologica 2015;100:370-6.
Verner J, Trbusek M, Chovancova J et al. NOD/SCID ILRγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle-cell lymphoma using permanent cell lines. Leuk Lymphoma 2015;56:3198-206.
te Raa GD, Moerland PD, Leeksma AC, Derks IA, Yigittop H, Laddach N, Loden-van Straaten M, Navrkalova V, Trbusek Met al. Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation dependent probe amplification. Cell Death Dis. 2015 Aug 6;6:e1852.
Zemanova J, Hylse O, Collakova J, Vesely P, Oltova A, Borsky M, Zaprazna K, Kasparkova M, Janovska P, Verner J, Kohoutek J, Dzimkova M, Bryja V, Jaskova Z, Brychtova Y, Paruch K, Trbusek M. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells. Oncotarget. 2016 Aug 19. doi: 10.18632/oncotarget.11388. [Epub ahead of print]
